Pharmacotherapy for breakthrough cancer pain

Area of Science:

• Pharmacology and Pain Management
• Oncology and Palliative Care

Background:

• Breakthrough pain (BTP) is a temporary, severe pain flare-up in patients with otherwise controlled chronic pain.
• Traditional oral opioids often have a slow onset, making them less suitable for the rapid relief required for BTP episodes.
• Transmucosal drug delivery offers a promising alternative for faster pain management.

Purpose of the Study:

• To review the efficacy and safety of rapid-onset opioids (ROOs) for managing breakthrough pain (BTP).
• To compare the effectiveness of transmucosally administered opioids with traditional oral formulations.

Main Methods:

• Review of studies evaluating various rapid-onset opioid (ROO) formulations, including oral transmucosal fentanyl citrate, buccal tablets, sublingual, and intranasal sprays.
• Analysis of clinical data on the onset of action, efficacy, and safety profiles of these ROOs.
• Consideration of patient populations, specifically opioid-tolerant individuals on at least 60 mg oral morphine equivalents daily.

Main Results:

• Rapid-onset opioids (ROOs) provide clinically significant pain relief within 10-15 minutes of administration.
• Various ROO formulations (e.g., fentanyl citrate, buccal tablets, nasal sprays) demonstrated superior efficacy compared to placebo and oral opioids.
• Long-term studies confirm the sustained efficacy and acceptable safety profile of ROOs in managing BTP.

Conclusions:

• Rapid-onset opioids (ROOs) represent a significant advancement in breakthrough pain (BTP) management, offering faster and more effective relief.
• Transmucosal delivery systems are well-suited for potent opioids like fentanyl, providing rapid pain control for opioid-tolerant patients.
• ROOs are a valuable therapeutic option for patients experiencing breakthrough pain, improving quality of life.